Claroid Pharma Files IPO Draft Papers To Offer 1.26 Crore Shares: Here Are The Key Risk Factors

The company plans to utilise the net proceeds from the fresh issue towards funding capital expenditure for setting up a new pharmaceutical manufacturing facility on its existing land.
Key takeaways
- Category: Corporate Action.
Why it matters
A routine update. Use the price and stock snapshot to gauge how the market is responding.













